Christopher J. Reinhard, Chairman of the Board and Chief Executive Officer
Mr. Reinhard is co-founder of Cardium and has served as a director and the Chief Executive Officer,
President and Treasurer of Cardium since its inception in December 2003. Mr. Reinhard has played a leadership role in the pre-clinical, clinical and commercial development of the Generx program. In 1996, he was co-founder of Collateral Therapeutics, which licensed the Generx technology covering methods of cardiovascular gene therapy based on discoveries by researchers at the University of California, San Diego. He helped lead a five year strategic partnership with Schering AG that supported the clinical development of Generx and ultimately led Schering to purchase Collateral for approximately $160 Million. After Schering was subsequently acquired by Bayer, Mr. Reinhard and Dr. Dylan-Hyde co-founded Cardium Therapeutics to re-acquire rights to the technology and advance the Generx program as a non-surgical approach to the treatment of coronary heart disease. He is also Chief Executive Officer and President of Tissue Repair Company, a wholly-owned subsidiary of Cardium, since August 2006. He served as a director and Chief Executive Officer of Cardium’s subsidiary InnerCool Therapies Inc., from its acquisition in March 2006 until sale of the business to Royal Philips Electronics in July 2009; and its subsidiary To Go Brands Inc., from its acquisition in September 2012 until sale of the business to Cell-Nique Corporation in November 2013. Previously, he served as a director and the Chief Executive Officer, President and Treasurer of Aries Ventures Inc. from October 20, 2005 through its merger with Cardium in January 2006. He also served as Chief Financial Officer of Aries Ventures Inc. from October 20, 2005 to November 16, 2005. For the past fifteen years, Mr. Reinhard has focused on the commercial development of innovative therapeutics and medical devices. Before founding Cardium, he was a co-founder of Collateral Therapeutics, Inc., a former Nasdaq listed public company, and served as a director (from 1995) and President (from 1999) of Collateral Therapeutics until the completion of its acquisition by the Schering AG Group (now part of Bayer HealthCare) in 2002. He continued as Chief Executive of Collateral Therapeutics through December 2004. Mr. Reinhard played a major role in effecting Collateral Therapeutics’ initial public 5 offering in 1998, and the sale of Collateral Therapeutics to Schering. From 2004-2008, Mr. Reinhard was Executive Chairman of Artes Medical, Inc., a publicly-traded medical technology company; and prior to cofounding Collateral Therapeutics, he was Vice President and Managing Director of the Henley Group, a publicly traded diversified industrial and manufacturing group, and Vice President of various public and private companies created by the Henley Group through spin-out transactions, including Fisher Scientific Group, a leading international distributor of laboratory equipment and test apparatus for the scientific community, Instrumentation Laboratory and IMED Corporation, a medical device company. Mr. Reinhard received a B.S. in Finance and an M.B.A. from Babson College.
Gabor M. Rubanyi, M.D., PH.D., Chief Scientific Officer
Dr. Rubanyi has been the Chief Scientific Officer of Cardium since June 2006. From November 2005 until March 2006, he provided consulting services to Cardium. In March 2006, Dr. Rubanyi became an employee and a Scientific Advisor of Cardium. Before joining Cardium in March 2006, Dr. Rubanyi was Vice President of Gene Therapy at Berlex Biosciences (a subsidiary of Berlex Laboratories, the U.S. pharmaceutical affiliate of the Schering AG Group, Germany), and Adjunct Professor at the University of California, Davis. He initiated and played a leading role in the Angiogenic Gene Therapy for Coronary Artery Disease project at Schering/Berlex. Formerly, Dr. Rubanyi was Director of Vascular and Endothelial Research at Berlex (1992-1999), Director of the Institute of Pharmacology at Schering AG, Research Center, Berlin, Germany (1990-1992), Director of Pharmacology at Berlex Laboratories (1987-1990), and Associate Professor at the Mayo Clinic Medical School (1983-1987). Since 2006, Dr. Rubanyi has served as a director of Hybrid Systems, Ltd., a private, United Kingdom biotech company. Dr. Rubanyi is the author or co-author of 22 books and over 325 research articles, serves as an editorial board member to several biomedical journals and is the founder of the biomedical journal Endothelium. He also is a member of numerous American and international scientific societies. His pioneering work on the nature and characterization of endothelium-derived relaxing factors (nitric oxide) and contracting factors (endothelin) contributed substantially to the Company’s present knowledge about endothelial control of vascular function in health and disease, including angiogenesis.
Robert L. Engler, M.D., Chief Medical Advisor
Dr. Engler was co-founder of Collateral Therapeutics and served as a Director from 1995 to 2000 and as Vice President — Medical Director from 1995 through 1998. Currently, Dr. Engler is Professor of Medicine Emeritus at the University of California, San Diego (UCSD). He was Professor of Medicine at UCSD, Associate Chief of Staff for Research and Development at the Veterans’ Affairs Medical Center, and a faculty member of the Institute for Biomedical Engineering at UCSD. He served as director of Coronary Care at the VA Hospital and was a clinical cardiologist until 2001 when he retired from UCSD and the VA Hospital to continue his work in the development of innovative agents for cardiovascular therapy. From 1985 to 1997, Dr. Engler was a Scientific Advisor to Gensia. Dr. Engler is a director of Halozyme Therapeutics, a publicly-traded biotechnology company. He received a B.A. in Physics from the University of North Carolina and his medical degree from Georgetown University.
Lois A. Chandler, Ph.D., Vice President, Biologics Development
Dr. Chandler has served as Vice President, Biologics Development of Cardium since July 2010 and served as Senior Director, Product Development of Cardium’s wholly-owned subsidiary, Tissue Repair Company, from August 2006 to July 2010. Dr. Chandler has 17 years of professional experience in biopharmaceutical design and clinical development, Chemistry, Manufacturing and Controls, Quality Control and custom DNA vector design. Prior to joining Tissue Repair Company in January 2006, Dr. Chandler served as Associate Director, Vector Development for Selective Genetics Inc., a company that developed targeted viral and non-viral DNA therapeutics for dermal, cardiovascular, and orthopedic tissue repair. At Selective Genetics, Dr. Chandler oversaw the developmental Chemistry, Manufacturing and Control efforts related to Excellarate and Excellagen as well as other targeted gene therapy preclinical programs. She also served as Supervisor of the Molecular Biology, Analytical Development and Assay Development departments. Prior to Selective Genetics, Dr. Chandler was employed by Prizm Pharmaceuticals as a Senior Scientist, Molecular Biology designing novel recombinant mitotoxins for proliferative disorders. Dr. Chandler received a B.S. in Chemistry from Stanford University, Palo Alto, CA, and a Ph.D. in Biochemistry from the University of Southern California with emphasis on the epigenetics of cancer.